Resources Repository
-
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Evidence Synthesis | Preferences/Values | Technology Assessment | North America | Health Outcomes | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Evidence Synthesis | Technology Assessment | North America | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Evidence Synthesis | Technology Assessment | North America | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Health/Medicine -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Technology Assessment | North America | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | Europe -
GuidelinesPublication 2015USPSTF Procedure Manual
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the …
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the Task Force to ensure that its recommendations are scientifically sound, reproducible, and well documented. The Manual provides a high-level description of the Task Force’s structure, governance, and processes for selecting topics, reviewing evidence, soliciting and responding to public input, and arriving at a recommendation. It is intended as a guide for anyone who is interested in the Task Force, Task…
Evidence Synthesis | Technology Assessment | North America | Priority Setting/Ethics | Health Systems | Policy/Regulation | Government/Law | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Technology Assessment | North America | Priority Setting/Ethics | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | North America | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | North America | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Government/Law -
ReportPublication 2021What It Means to Be a Science-Literate Citizen in a Digital World
Science literacy is often held up as crucial for avoiding science-related misinformation and enabling more …
Science literacy is often held up as crucial for avoiding science-related misinformation and enabling more informed individual and collective decision-making. But research has not yet examined whether science literacy actually enables this, nor what skills it would need to encompass to do so. This report addresses three questions to outline what it should mean to be science literate in today’s world: (1) How should we conceptualize science literacy? (2) How can we achieve this science…
Preferences/Values | North America | Decision Psychology | Social Determinants | Culture/Society | Energy/Engineering | Education/Labor | Health/Medicine | Science/Technology | Global